详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Case Report: Durable complete response of metastatic hepatocellular carcinoma with asymptomatic hyperamylasemia to combined immunotherapy of anti-cytotoxic T lymphocyte-associated antigen 4 plus anti-programmed cell death-1 antibodies

57| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. [2]Clinical Medicine Research Center for Hepatic Surgery of Hubei Province, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. [3]Hubei Key Laboratory of Hepato-Pancreatic-Biliary Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

出处：

DOI：

ISSN：

关键词： hepatocellular carcinoma asymptomatic hyperamylasemia PD-1 inhibitor CTLA-4 inhibitor combined immunotherapy

摘要：

Combined immunotherapy has shown promising results in the treatment of advanced HCC, whereas the priority population that would respond to the combined immunotherapy is still elusive. In addition, HCC with asymptomatic hyperamylasemia was not reported previously.An aged patient was diagnosed as HCC with BCLC stage C (bone metastasis). Notably, this patient showed asymptomatic hyperamylasemia. The patient was then enrolled in a trial evaluating combined immunotherapy of anti-PD-1 antibody sintilimab (IBI308) plus anti-CTLA-4 antibody (IBI310) in advanced HCC. After being treated with combined immunotherapy, this patient rapidly achieved complete response (CR) according to mRECIST criteria or immune partial response (iPR) according to iRECIST criteria and maintain the CR state for more than 12 months. Interestingly, serum levels of amylase and lipase in this patient were reduced after treatment.We reported, for the first time, a case of metastatic HCC with asymptomatic hyperamylasemia, and suggested that HCC patients with asymptomatic hyperamylasemia may benefit from combined immunotherapy of anti-CTLA-4 and PD-1 antibodies.Copyright © 2023 Gao, Chang, Chen, Zhang, Zhang, Luo and Ding.

基金：

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 2 区

医学

小类 | 2 区免疫学

最新[2025]版：

大类 | 2 区医学

小类 | 2 区免疫学

JCR分区：

出版当年[2021]版：

Q1 IMMUNOLOGY

最新[2023]版：

Q1 IMMUNOLOGY

影响因子： 5.7 最新[2023版] 6.8 最新五年平均 8.787 出版当年[2021版] 8.877 出版当年五年平均 7.561 出版前一年[2020版] 7.3 出版后一年[2022版]

第一作者：

第一作者单位： [1]Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. [2]Clinical Medicine Research Center for Hepatic Surgery of Hubei Province, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. [3]Hubei Key Laboratory of Hepato-Pancreatic-Biliary Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

共同第一作者：

通讯作者：

通讯机构： [1]Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. [2]Clinical Medicine Research Center for Hepatic Surgery of Hubei Province, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. [3]Hubei Key Laboratory of Hepato-Pancreatic-Biliary Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

Case Report: Durable complete response of metastatic hepatocellular carcinoma with asymptomatic hyperamylasemia to combined immunotherapy of anti-cytotoxic T lymphocyte-associated antigen 4 plus anti-programmed cell death-1 antibodies

文献详情

相关文献